Company intelligence / Profile preview
DynPort Vaccine Company
Frederick, Maryland, USAgdit.com ↗
- Ownership
- Private
- Employees
- ~130
- Development stage
- Commercial
01
Overview
DynPort has successfully advanced six biodefense products into clinical development and one to licensure. Notably, its recombinant plague vaccine candidate rF1V reached Phase 2 trials, and the company licensed vaccinia immune globulin for smallpox vaccine adverse reactions. DVC specializes in managing complex product development programs through preclinical, clinical, manufacturing, regulatory submission stages—primarily under U.S. government contracts[1][5][10].
- Therapeutic areas
- NeurologyInfectious Diseases
- Modalities
- VaccineBiologicSmall molecule
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Altimmune (COVID intranasal vaccines)Quintiles Transnational Corp. (Phase I trial management)U.S. Department of Defense Joint Vaccine Acquisition Program ("JVAP")National Institute of Allergy and Infectious Diseases ("NIAID")
Beyond the preview
Go deeper on DynPort Vaccine Company.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DynPort Vaccine Company.